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An elevated low-density lipoprotein cholesterol (LDL-C)
is a major established risk factor for the development of
atherosclerotic cardiovascular disease. The standard regi-
men for the treatment of elevated LDL-C relies on the
statins, which inhibit endogenous cholesterol synthesis,
reducing the regulatory pool of intracellular cholesterol,
thus resulting in increased transcription of the LDL re-
ceptor (LDLR) gene. The LDLR, especially that present
on the surface of hepatocytes, is mainly responsible for
clearance of LDL from the plasma. The transcription factor
mediating this change is sterol regulatory element-binding
protein (SREBP), especially SREBP2. In addition to in-
creased transcription of the LDLR gene, many other genes
are transcribed at a higher rate. Among these genes is the
gene encoding proprotein convertase subtilisin/kexin type 9
(PCSK9) (1).See page 2365PCSK9 is an inhibitor of the LDLR, mostly as a result of
the enhancement of the receptor degradation in the lyso-
some. Thus, attenuation of PCSK9 function reduces LDLR
degradation. Inhibition of PCSK9 represents a strategy in
addition to statin treatment to lower LDL-C levels to a
healthy range and represents a treatment for those who
do not tolerate high-dose statin therapy. Recent years have
seen much progress in the development of approaches to the
reduction of PCSK9 levels, whether using antisense tech-
nology or monoclonal antibodies (2,3).
Classical familial hypercholesterolemia (FH) is attribut-
able to mutations in the gene for LDLR, and a large number
of such mutants have been catalogued (4). Inheritance of
the phenotype is by a dominant mechanism. The LDLR is
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paper to disclose.7 ligand-binding domains (exons 2 to 6); an epidermal
growth factor–like (EGF-like) repeat (exons 7 to 14), a
domain that plays a role in the trafﬁcking of the receptor
from the endoplasmic reticulum to the Golgi as well as in
the recycling of the receptor from the endosome back to
the plasma membrane, an O-linked glycosylation domain
(exon 15), and a cytoplasmic tail (exons 17 and 18) that is
involved in receptor internalization. On the plasma mem-
brane, the LDLR is found in coated pits, where it binds
LDL and the complex is internalized, trafﬁcking to the
endosomal compartment. Acidiﬁcation in the endosome
promotes dissociation of LDL from the receptor, which
recycles to the plasma membrane, while the LDL moves to
the lysosome, where it is degraded. There is an average of
about 20 such cycles before the receptor itself is degraded.
The interactions between LDL, PCSK9, and the LDLR
are complex. PCSK9 is a secreted protein and associates
with the extracellular domain of the LDLR. Its effect on
LDLR degradation, however, is intracellular. The catalytic
activity of the kinase is not required for PCSK9 to inﬂuence
LDLR turnover, either steering the complex with the re-
ceptor to the lysosomes where it is degraded or inhibiting
its recycling (5,6). In the study in this issue of the Journal,
Lambert et al. (7) asked whether PCSK9 is equally effective
in reducing the level of LDLR, whether of normal structure
or altered by mutations sufﬁciently to generate the FH
phenotype. They studied 3 receptor missense mutations
originally described in South African Afrikaners (designated
as Afrikaner mutations [4]). These mutations fall into 2 of
the 5 functional classes of LDLR mutations. Two muta-
tions, D154N and D206E (exon 4), are class 2 mutations
(i.e., defective in maturation and/or transport from the
endoplasmic reticulum to the Golgi), whereas the third
mutation, V408M (exon 9), is defective in recycling and
belongs to class 5. Homozygote cells from the D206E
mutants exhibit 5% to 15% of LDL activity, whereas
V408M has <2% activity (4). A relatively large number of
heterozygous patients bearing each of these mutant receptors
were assessed for baseline lipoprotein characteristics (i.e.,
before any statin treatment was initiated). The researchers
also studied primary ﬁbroblasts and lymphocytes derived
from a smaller subset of each of the mutant patients. These
cells were cultured in a medium to which recombinant
PCSK9 was added. They noted that PCSK9 addition
reduced cell surface expression of mutant and normal re-
ceptors in both cell types (measured by ﬂow cytometry) by
about the same percentage. In heterozygous FH cells, the
cell surface contained a mixture of normal and mutant re-
ceptors, with the former predominating to various extents
depending on the nature of the mutation. To avoid this
complexity, the researchers transfected HEK cells, either
expressing or not expressing PCSK9, with plasmids
encoding either normal or mutant receptor. In this case,
the receptors expressed were homogeneous, either wild
type or mutant. For the 2 class 2 mutants, coexpression of
PCSK9 resulted again in the same percentage reduction of
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expressing cells. For the class 5 mutant, V408M, the cells
expressed very few surface receptors and were quite unre-
sponsive to PCSK9 presence. Being a recycling recep-
tor mutant, LDLR-V408M does not mature intracellularly.
Maturation can be detected by sizing the receptor. The
intracellular immature form is 120 kDa, whereas the fully
glycosylated mature form is 160 kDa. Despite the ineffec-
tiveness of PCSK9 on the class 5 cell surface receptor
mutant, it did reduce the level of immature 120-kDa pro-
tein, showing that PCSK9 can act intracellularly.
This study is valuable in correlating patients’ in vivo
lipoprotein metabolism before treatment with the behavior
of their ﬁbroblasts and lymphocytes in culture and the
response to added PCSK9. All 3 groups of heterozygous
patients with FH exhibited a signiﬁcant increase in plasma
PCSK9 concentration. The excursions and regulation of
PCSK9 are complex. Approximately 30% of the circulating
PCSK9 is bound to LDL (8) and is cleared as a complex by
the LDLR. PCSK9 may also bind to the LDLR indepen-
dently of LDL and may be internalized with the receptor.
The half-life of injected PCSK9 varies as a function of
the LDLR, being fast with normal levels of functional
LDLR, slower with heterozygous mutant LDLR, and
slowest when the LDLR is completely absent. Thus, in
patients, there is a good correlation between LDL-C and
PCSK9 in the plasma. This relationship is disrupted with
statin treatment when the levels of LDL-C decline and
PCSK9 increase.
PCSK9 independently of LDL binds to the LDLR at
the N-terminal portion of the EGF-like repeat (EGFA
exon 7), consisting of residues 293 to 332. Clearly, none of
the mutants in this study fell within this interval. Two
residues that signiﬁcantly inﬂuence PCSK9 binding are
Leu318 (9) and Asp310. (10). It would be of interest to
study PCSK9 function in mutants falling within this in-
terval, especially those affecting the 2 named residues. For
such experiments, the outcome measure might be the sta-
bility of the 120-kDa intracellular precursor. The synthetic
peptide of residues 293 to 332 would be expected to block
the interaction of PCSK9 with the receptor and hence
improve receptor stability in vivo or in a culture system
similar to that employed by Lambert et al. (7). Strategic
residues within this 40–amino acid stretch could be altered
to dissect effects in vivo on PCSK9 binding to the cell
surface receptor.
Most of the PCSK9 function is at the liver. The
precise basis for this organ speciﬁcity is not clear. LDLR
function is important in the adrenal gland, yet the in-
jection of PCSK9 has no effect on the adrenal receptor.
Also, knockout of PCSK9 has no effect on the adrenal
receptor. The pathway for LDLR internalization is not
precisely the same for hepatocytes, lymphocytes, and ﬁ-
broblasts. Thus, the cytoplasmic adaptor protein auto-
somal recessive hypercholesterolemia (ARH) is required
for LDLR internalization in hepatocytes and lymphocytes.PCSK9 can promote degradation of LDLR in ﬁbroblasts
lacking ARH (6). One of the limitations of this study,
recognized by the researchers, was that they were unable
to study the interaction of LDLR and its mutants with
PCSK9 in liver cells.
The authors concluded that elevated PCSK9 levels were
equally detrimental for heterozygous patients with FH
and patients with nonfamilial hypercholesterolemia (non-
FH). Their assessment of the cell surface receptor was
accomplished by immunoﬂuorescence in a ﬂow cytometer,
measuring the amount of receptor, rather than the amount
of functional receptor. Actually, despite their culture
experimental results, in vivo elevated levels of PCSK9 in
heterozygous patients with FH may be more deleterious
than in patients with non-FH. This is because a smaller
fraction of the total cell surface receptor is functional
in heterozygotes, and a larger number of functional cell
surface receptors may be degraded in the presence of the
elevated PCSK9 levels. If this is indeed the case, PCSK9
inhibition may be functionally more beneﬁcial in heterozy-
gous patients.
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